ISIN
PLBCLTX00019
Ticker
BCX
Sector
Sub-Industry
Country
Poland
Year Founded
2018
Bioceltix is a team of experts working on innovative therapies for veterinary use. We work on biopharmaceuticals that harness the immunomodulatory properties of mesenchymal stem cells. We develop them following the highest quality and safety standards. We possess cutting-edge research and production facilities, cooperate with ambitious scientists, and operate under a well-developed business model. Our goal is to market new, effective solutions in the field of veterinary medicine.
The safety and efficacy of Bioceltix products will also be verified through field clinical trials carried out in accordance with Good Clinical Practice (GCP). The independent trials will be conducted in leading veterinary centres, under the supervision of the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL).
Worldwide
PLBCLTX00019
259400QZD5JYK8SLZU51
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.